Standard Glass Lining Technology Limited
Open Date: | 06-Jan-2025 |
Close Date: | 08-Jan-2025 |
Allotment Date: | 09-Jan-2025 |
Listing Date: | 13-Jan-2025 |
Listing Price: | N/A |
Face Value: | ₹₹10 Per Equity Share Per Equity Share |
Issue Price: | ₹₹133-140 per equity share Per Equity Share |
Issue Size: | Total ₹410.05 Cr : #Fresh Issue : 1,50,00,000 shares(aggregating up to ₹210.00 Cr) |
Market Lot (Min Amount): | 107 Shares (₹14,980/-) |
Earning Per Share(EPS) | N/A |
P/E Ratio | N/A |
RoNW | N/A |
Net Asset Value (NAV) - Post Issue: | N/A/- |
Total Assets | Total Revenue | Profit After Tax | |
---|---|---|---|
31 Mar,2024 | 665.38 | 549.68 | 60.01 |
31 Mar,2023 | 347.79 | 500.08 | 53.42 |
31 Mar,2022 | 298.11 | 241.5 | 25.15 |
Pre Issue Share Holding | N/A |
Post Issue Share Holding | N/A |
1. Nageswara Rao Kandula |
2. Kandula Krishna Veni |
3. Kandula Ramakrishna |
4. Venkata Mohana Rao Katragadda |
5. Kudaravalli Punna Rao |
6. M/s S2 Engineering Services |
Established in 2012, Standard Glass Lining Technology Limited is an India-based company that deals with the production of special engineering equipment for pharmaceutical and chemical industries. It provides a turnkey solution, involving design, engineering, manufacturing, assembly, and installation, for the entire manufacturing value chain.
They encompass, reaction systems, storage and separation systems, and dryings systems, made from a glass-lined material, and nickel alloys, stainless steel. The company has the most advanced manufacturing units which are eight in number spread over Hyderabad and a very effective sales network all across India, thus ensuring adequate service and delivery.
Operating with marquee clients as Aurobindo Pharma, Laurus Labs and Cadila Pharmaceuticals, amongst others, the company also offers customized solutions, advance technology, and a healthy growth record.
Choose Standard Glass Lining for innovative and reliable solutions in the pharmaceutical and chemical sectors.
No financial information whatsoever published anywhere, within this application, should be considered as an advise to buy or sell securities or invest in IPOs, or as guide to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
Also we are not a SEBi registered analyst comapny. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this application. Above information is based on information available as on date coupled with market perceptions.
If you are agree with app tems and condition to use the app.
Thank you.